Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse

Investigational New Drugs

Volumn 24, Issue 6, 2006, Pages 459-464

  Sale, S ^a,c   Tunstall, R G ^a   Ruparelia, K C ^b   Butler, P C ^b   Potter, G A ^b   Steward, W P ^a   Gescher, A J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Analogue development; ApcMin+ mouse; Chemoprevention

Indexed keywords

3,4 METHYLENEDIOXY 3',4',5' TRIMETHOXYCHALCONE; ANTINEOPLASTIC AGENT; CYTOCHROME P450 1B1; DMU 117; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADENOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL CARCINOMA; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CHALCONE; COLON; DISEASE MODELS, ANIMAL; GENES, APC; HEMATOCRIT; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MICE; MICE, INBRED C57BL; PRODRUGS; PROTEIN-TYROSINE KINASES;

EID: 33747742512     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-5947-0     Document Type: Article

References (30)

1. Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, Zeslawski W, Kamionka M, Rehm T, Muhlhahn P, Schumacher R, Hesse F, Kaluza B, Voelter W, Engh RA, Holak TA (2001) Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40:336-344
2. Iwashita K, Kobori M, Yamaki K, Tsushida T (2000) Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci Biotechnol Biochem 64:1813-1820
3. Lawrence NJ, McGown AT, Ducki S, Hadfield JA (2000) The interaction of chalcones with tubulin. Anticancer Drug Des 15:135-141
4. Potter GA, Butler PC, Wanogho E (2001) Chalcone Therapeutic Agents. British Patent Application GB 01/01341
5. Potter GA, Butler PC (2003) 3,4-Methylenedioxy Chalcones as Therapeutic Agents. GB 0123777.5 (2001), PCT:GB02/00406 (2002), WO 03/028713
6. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57:3026-3031
7. Stanley LA, Ball MT, Eaden J, Mayberry J, McKay H, Potter GA, Rolls S, Burke MD (2001) Cytochrome P450 CYP1B1 in the early stages of colon tumour development. Drug Metabol Rev 33:62
8. Gibson P, Gill JH, Khan PA, Seargent JM, Martin SW, Batman PA, Griffith J, Bradley C, Double JA, Bibby MC, Loadman PM (2003) Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: Implications for drug development. Mol Cancer Ther 2:527-534
9. Butler PC, Ruparelia KC, Ijaz T, Tan HL, Wilsher NE, Perry PJ, Burke MD, Potter GA (2003) DMU135: A CYP1B1 activated tyrosine kinase inhibitor prodrug with tumour selective activity. Br J Cancer 87:S33
10. Gibson P, Loadman PM, Shnyder S, Potter GA, Butler PC (2003) Bioavailability of novel anticancer chalcones in in vivo Xenografts. Br J Cancer 88:S27
11. Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, Threadgill DW (2002) Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 99:1521-1526
12. Corpet DE, Pierre F (2003) Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 12:391-400
13. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell DR, Raymond R, Stables R, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 77:1-10
14. + in intestinal adenomas from Min mice. Cancer Res 54:5947-5952
15. Strumia MM, Sample AB, Hart ED (1954) An improved micro hematocrit method. Am J Clin Pathol 24:1016-1024
16. Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 92:1331-1346
17. Fischer OM, Streit S, Hart S, Ullrich A (2003) Beyond Herceptin and Gleevec. Curr Opin Chem Biol 7:490-495
18. Sansom OJ, Stark LA, Dunlop MG, Clarke AR (2001) Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice. Cancer Res 61:7060-7064
19. Perkins S, Clarke AR, Steward W, Gescher A (2003) Age-related difference in susceptibility of Apc(Min/+) mice towards the chemopreventive efficacy of dietary aspirin and curcumin. Br J Cancer 88:1480-1483
20. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ (2002) Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 11:535-540
21. Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, Gescher AJ (2005) Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer 115:194-201
22. Cortes J, O'Brien S, Quintas A, Giles F, Shan J, Rios MB, Talpaz M, Kantarjian H (2004) Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 100:2396-2402
23. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R (2002) Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034-3038
24. Sawaki A, Yamao K, Nakamura T, Suzuki T, Okubo K, Hara K, Kawai H, Yamamura Y, Ito S, Mochiduki Y, Ohno R (2004) A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients. J Gastroenterol 39:329-333
25. Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Martucci C, Newmark HL, Bertagnolli MM (2000) Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 21:921-927
26. Borrelli F, Izzo AA, Di Carlo G, Maffia P, Russo A, Maiello FM, Capasso F, Mascolo N (2002) Effect of a propolis extract and caffeic acid phenethyl ester on formation of aberrant crypt foci and tumors in the rat colon. Fitoterapia 73(Suppl 1):S38-S43
27. Liao HF, Chen YY, Liu JJ, Hsu ML, Shieh HJ, Liao HJ, Shieh CJ, Shiao MS, Chen YJ (2003) Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion, and metastasis. J Agric Food Chem 51:7907-7912
28. Michaluart P, Masferrer JL, Carothers AM, Subbaramaiah K, Zweifel BS, Koboldt C, Mestre JR, Grunberger D, Sacks PG, Tanabe T, Dannenberg AJ (1999) Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Cancer Res 59:2347-2352
29. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60:5040-5044
30. Frantz S (2004) Vioxx risk could signify trouble in class. Nat Rev Drug Discov 3:899-901